Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
Summary of all GSEA data identified in AraC- versus PBS-treated AML cells in PDX and LOW versus HIGH Responder to AraC in PDX.
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
HIGH CD36 gene signature generated from upregulated genes in AML patients that express the most CD36 mRNA compared to that of the lowest expression of CD36 in TCGA cohort.
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
Up- and down-regulated genes in AML patients that have the lower response (LowR) to AraC in vivo in NSG mice compared to high responder (HighR) to AraC in vivo using PDX assay.
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
(1) Gene signatures of AraC residual AML blasts in vivo from three AML patients xenografted and treated with AraC. (2) Functional analyses of up-regulated genes of AraC residual AML blasts in vivo. (3) Functional analyses of down-regulated genes of AraC residual AML …
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
(1) HIGH OXPHOS gene signature generated from HIGH versus LOW OXPHOS AML cell lines untreated or treated with metformin. (2) Functional analysis of upregulated genes encoding for mitochondrial proteins in untreated HIGH versus LOW OXPHOS AML cell lines.
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
Supplementary Methods. Supplementary Figure S1. Clinical distributions of AML patients from TUH and 3 independent patient cohorts. Supplementary Figure S2. In vivo treatment with 60 mg/kg/d of cytarabine (AraC) given daily for 5 days induces a significant reduction of the total cell …
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
Determination of LICs frequency in bone marrow and spleen from AraC- or PBS-treated AML-xenografted NSG mice using in vivo limiting dilution assay.
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
(1) Clinical characteristics of 27 AML patients used in this study for engraftment in NSG mice, including the 25 ones treated in vivo with 60 mg/kg/d cytarabine (AraC) for 5 days. (2) Clinical and mutational characteristics of AML cell lines used in …
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
(1) Clinical characteristics of 27 AML patients used in this study for engraftment in NSG mice, including the 25 ones treated in vivo with 60 mg/kg/d cytarabine (AraC) for 5 days. (2) Clinical and mutational characteristics of AML cell lines used in …
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
(1) Gene signatures of AraC residual AML blasts in vivo from three AML patients xenografted and treated with AraC. (2) Functional analyses of up-regulated genes of AraC residual AML blasts in vivo. (3) Functional analyses of down-regulated genes of AraC residual AML …
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
Determination of LICs frequency in bone marrow and spleen from AraC- or PBS-treated AML-xenografted NSG mice using in vivo limiting dilution assay.
Thomas Farge, Estelle Saland, Fabienne de Toni, Nesrine Aroua et autres
Supplementary Methods. Supplementary Figure S1. Clinical distributions of AML patients from TUH and 3 independent patient cohorts. Supplementary Figure S2. In vivo treatment with 60 mg/kg/d of cytarabine (AraC) given daily for 5 days induces a significant reduction of the total cell …
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.
L'essentiel de l'actu tech du Burkina & d'Afrique, chaque semaine dans votre boîte mail.
Gratuit · sans spam · désinscription en un clic